ABOS
Acumen Pharmaceuticals Inc.
Company Overview
| Mkt Cap | $115.70M | Price | $2.57 |
| Volume | 319.07K | Change | -2.47% |
| P/E Ratio | -1.1 | Open | $2.76 |
| Revenue | -- | Prev Close | $2.63 |
| Net Income | $-102.3M | 52W Range | $0.86 - $3.60 |
| Div Yield | N/A | Target | $7.50 |
| Overall | 48 | Value | 60 |
| Quality | -- | Technical | 36 |
No chart data available
About Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize Sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Latest News
BTIG Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS)
BTIG Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS)
Acumen Pharmaceuticals’ Earnings Call: Promise Amid Pressure
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABOS | $2.57 | -2.5% | 319.07K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Acumen Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW